Coronavirus (COVID-19) notice

In accordance with the Quebec government directive, McGill University will remain closed until further notice. As a result, kindly note that the McGill Biomedical Ethics Unit team is working remotely.

The best way to reach us is via ssom [at] (email )

Annual Reports

Publication List

  • Bereza, E., The use of clinical databases in disease outcomes research: Is the ethics of IRB review keeping up?, Multiple Sclerosis Journal, September 2017, Vol 23, No 10, pp. 1325-27.
  • Karkazis K, Fishman JR. Tracking U.S. Professional Athletes: The Ethics of Biometric Technologies. The American journal of bioethics : AJOB. 2017;17(1):45-60.
  • Aungst H, Fishman JR, McGowan ML. Participatory Genomic Research: Ethical Issues from the Bottom Up to the Top Down. Annual review of genomics and human genetics. 2017;18:357-367.
  • Meagher KM, McGowan ML, Settersten RA, Jr., Fishman JR, Juengst ET. Precisely Where Are We Going? Charting the New Terrain of Precision Prevention. Annual review of genomics and human genetics. 2017;18:369-387.
  • McGowan ML, Choudhury S, Juengst ET, Lambrix M, Settersten RA, Fishman JR. “Let’s pull these technologies out of the ivory tower”: The politics, ethos, and ironies of participant-driven genomic research. BioSocieties. 2017;12(4):494-519.
  • Karsoho H, Wright DK, Macdonald ME, Fishman JR. Constructing physician-assisted dying: the politics of evidence from permissive jurisdictions in Carter v. Canada. Mortality. 2017;22(1):45-59.
  • Kimmelman J, Carlisle B, Gönen M. Drug development at the portfolio level is important for policy, care decisions and human protections. JAMA. 2017;318(11):1003-1004.
  • Benjamin D, Mandel DR, Kimmelman J. Can cancer researchers accurately judge whether preclinical reports will reproduce? PLOS Biology. 2017;15(6):e2002212
  • Hakala AK, Fergusson D, Kimmelman J. Nonpublication of trial results for new neurological drugs: A systematic review. Annals of neurology. 2017;81(6):782-789.
  • Neumann K, Grittner U, Piper SK, et al. Increasing efficiency of preclinical research by group sequential designs. PLOS Biology. 2017;15(3):e2001307.
  • Kimmelman J, Federico C. Consider drug efficacy before first-in-human trials. Nature. 2017;542(7639):25-27.
  • Mattina J, Carlisle B, Hachem Y, Fergusson D, Kimmelman J. Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic Review. PLoS Biology. 2017;15(2):e2000487.
  • Kimmelman J, Resnik DB, Peppercorn J, Ratain MJ. Burdensome Research Procedures in Trials: Why Less Is More. Journal of the National Cancer Institute. 2017;109(4).
  • Huang JY, King NB. Epigenetics Changes Nothing: What a New Scientific Field Does and Does Not Mean for Ethics and Social Justice. Public Health Ethics. 2018;11(1):69-81.
  • Voigt K, King NB. Out of Alignment? Limitations of the Global Burden of Disease in Assessing the Allocation of Global Health Aid. Public Health Ethics. 2017;10(3):244-256.
  • Benmarhnia T, Alexander S, Price K, Smargiassi A, King NB & Kaufman JS. The Heterogeneity of Vulnerability in Public Health: A Heat Wave Action Plan as a Case Study. Critical Public Health. 2017

Follow Biomedical Ethics on:

Back to top